Cargando…

Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease

Inhibition of the papain-like protease (PLpro) of SARS-CoV-2 has been demonstrated to be a successful target to prevent the spreading of the coronavirus in the infected body. In this regard, covalent inhibitors, such as the recently proposed VIR251 ligand, can irreversibly inactivate PLpro by formin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hognon, Cécilia, Marazzi, Marco, García-Iriepa, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143025/
https://www.ncbi.nlm.nih.gov/pubmed/35628665
http://dx.doi.org/10.3390/ijms23105855
_version_ 1784715703727685632
author Hognon, Cécilia
Marazzi, Marco
García-Iriepa, Cristina
author_facet Hognon, Cécilia
Marazzi, Marco
García-Iriepa, Cristina
author_sort Hognon, Cécilia
collection PubMed
description Inhibition of the papain-like protease (PLpro) of SARS-CoV-2 has been demonstrated to be a successful target to prevent the spreading of the coronavirus in the infected body. In this regard, covalent inhibitors, such as the recently proposed VIR251 ligand, can irreversibly inactivate PLpro by forming a covalent bond with a specific residue of the catalytic site (Cys(111)), through a Michael addition reaction. An inhibition mechanism can therefore be proposed, including four steps: (i) ligand entry into the protease pocket; (ii) Cys(111) deprotonation of the thiol group by a Brønsted–Lowry base; (iii) Cys(111)-S(−) addition to the ligand; and (iv) proton transfer from the protonated base to the covalently bound ligand. Evaluating the energetics and PLpro conformational changes at each of these steps could aid the design of more efficient and selective covalent inhibitors. For this aim, we have studied by means of MD simulations and QM/MM calculations the whole mechanism. Regarding the first step, we show that the inhibitor entry in the PLpro pocket is thermodynamically favorable only when considering the neutral Cys(111), that is, prior to the Cys(111) deprotonation. For the second step, MD simulations revealed that His(272) would deprotonate Cys(111) after overcoming an energy barrier of ca. 32 kcal/mol (at the QM/MM level), but implying a decrease of the inhibitor stability inside the protease pocket. This information points to a reversible Cys(111) deprotonation, whose equilibrium is largely shifted toward the neutral Cys(111) form. Although thermodynamically disfavored, if Cys(111) is deprotonated in close proximity to the vinylic carbon of the ligand, then covalent binding takes place in an irreversible way (third step) to form the enolate intermediate. Finally, due to Cys(111)-S(−) negative charge redistribution over the bound ligand, proton transfer from the initially protonated His(272) is favored, finally leading to an irreversibly modified Cys(111) and a restored His(272). These results elucidate the selectivity of Cys(111) to enable formation of a covalent bond, even if a weak proton acceptor is available, as His(272).
format Online
Article
Text
id pubmed-9143025
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91430252022-05-29 Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease Hognon, Cécilia Marazzi, Marco García-Iriepa, Cristina Int J Mol Sci Article Inhibition of the papain-like protease (PLpro) of SARS-CoV-2 has been demonstrated to be a successful target to prevent the spreading of the coronavirus in the infected body. In this regard, covalent inhibitors, such as the recently proposed VIR251 ligand, can irreversibly inactivate PLpro by forming a covalent bond with a specific residue of the catalytic site (Cys(111)), through a Michael addition reaction. An inhibition mechanism can therefore be proposed, including four steps: (i) ligand entry into the protease pocket; (ii) Cys(111) deprotonation of the thiol group by a Brønsted–Lowry base; (iii) Cys(111)-S(−) addition to the ligand; and (iv) proton transfer from the protonated base to the covalently bound ligand. Evaluating the energetics and PLpro conformational changes at each of these steps could aid the design of more efficient and selective covalent inhibitors. For this aim, we have studied by means of MD simulations and QM/MM calculations the whole mechanism. Regarding the first step, we show that the inhibitor entry in the PLpro pocket is thermodynamically favorable only when considering the neutral Cys(111), that is, prior to the Cys(111) deprotonation. For the second step, MD simulations revealed that His(272) would deprotonate Cys(111) after overcoming an energy barrier of ca. 32 kcal/mol (at the QM/MM level), but implying a decrease of the inhibitor stability inside the protease pocket. This information points to a reversible Cys(111) deprotonation, whose equilibrium is largely shifted toward the neutral Cys(111) form. Although thermodynamically disfavored, if Cys(111) is deprotonated in close proximity to the vinylic carbon of the ligand, then covalent binding takes place in an irreversible way (third step) to form the enolate intermediate. Finally, due to Cys(111)-S(−) negative charge redistribution over the bound ligand, proton transfer from the initially protonated His(272) is favored, finally leading to an irreversibly modified Cys(111) and a restored His(272). These results elucidate the selectivity of Cys(111) to enable formation of a covalent bond, even if a weak proton acceptor is available, as His(272). MDPI 2022-05-23 /pmc/articles/PMC9143025/ /pubmed/35628665 http://dx.doi.org/10.3390/ijms23105855 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hognon, Cécilia
Marazzi, Marco
García-Iriepa, Cristina
Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
title Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
title_full Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
title_fullStr Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
title_full_unstemmed Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
title_short Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease
title_sort atomistic-level description of the covalent inhibition of sars-cov-2 papain-like protease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143025/
https://www.ncbi.nlm.nih.gov/pubmed/35628665
http://dx.doi.org/10.3390/ijms23105855
work_keys_str_mv AT hognoncecilia atomisticleveldescriptionofthecovalentinhibitionofsarscov2papainlikeprotease
AT marazzimarco atomisticleveldescriptionofthecovalentinhibitionofsarscov2papainlikeprotease
AT garciairiepacristina atomisticleveldescriptionofthecovalentinhibitionofsarscov2papainlikeprotease